Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. [electronic resource]
Producer: 20060824Description: 715-6 p. digitalISSN:- 1592-8721
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Drug Resistance, Neoplasm -- drug effects
- Female
- Gene Expression Regulation, Neoplastic -- drug effects
- Genes, bcl-2
- Humans
- Immunotherapy
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Multicenter Studies as Topic -- statistics & numerical data
- Neoplasm Proteins -- genetics
- Prednisone -- administration & dosage
- Proportional Hazards Models
- Proto-Oncogene Proteins c-bcl-2 -- physiology
- Randomized Controlled Trials as Topic -- statistics & numerical data
- Risk
- Rituximab
- Survival Analysis
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.